{"name":"Sagent Pharmaceuticals, Inc.","slug":"sagent-pharma","ticker":"N/A","exchange":"Private (Nichi-Iko subsidiary)","domain":"sagentpharma.com","description":"Sagent Pharmaceuticals, Inc. is a generic pharmaceutical company focused on developing and commercializing generic injectable and ophthalmic products. The company's key products include generic versions of branded medications. Sagent Pharmaceuticals operates in the US market and has a portfolio of products in various therapeutic areas.","hq":"Schaumburg, Illinois","founded":0,"employees":"N/A","ceo":"Mark Donohue","sector":"Generic Pharmaceuticals","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":420000000,"revenueGrowth":323.3,"grossMargin":27.6,"rdSpend":29145000,"netIncome":-21882000,"cash":28962000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Lidocaine Hydrochloride patent cliff ($10.8M at risk)","drug":"Lidocaine Hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2027-06-01","label":"Dexamethasone patent cliff ($15.6M at risk)","drug":"Dexamethasone","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2022-04-28","type":"deal","headline":"Sagent Pharmaceuticals Acquires Rights to Generic Version of Branded Medication","summary":"Sagent Pharmaceuticals acquired the rights to a generic version of a branded medication from a third-party supplier.","drugName":"","sentiment":"positive"},{"date":"2020-02-27","type":"earnings","headline":"Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results","summary":"Sagent Pharmaceuticals reported its financial results for the fourth quarter and full year 2019, with revenue increasing by 10% year-over-year.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9HN252M2I2WW83UkZEWlk5ZXlxaGZIaDEzRlpZcTdqUlF2N3RtakpVSFA1b2RDamkxZlRpbHM0c0hwOU01ZVlwSTNieFhJZGNaSFY2ejB6b045SG5aa2xpUHdSQy13Nm8?oc=5","date":"2021-06-28","type":"pipeline","source":"Comparably","summary":"Amneal Pharmaceuticals NPS & Customer Reviews - Comparably","headline":"Amneal Pharmaceuticals NPS & Customer Reviews","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE15VWgzNWFGWFN3OFpKNHdxdEdMaHlnRWN6eldjdHhOQVZGQVBmQlNkbmJhelhrQmloUUJXeTIxeUR4T0NURVJUOTdtLWRFdzJNQ3hQQS10eHJNMVJyNG4xeGRzZnotQQ?oc=5","date":"2021-04-26","type":"pipeline","source":"Comparably","summary":"Hikma Pharmaceuticals NPS & Customer Reviews - Comparably","headline":"Hikma Pharmaceuticals NPS & Customer Reviews","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZUdiMUI2RERBcXVHOGg4c1g3Y0Z2QzhwcTF4NTBaazBsOEE0MXdPTl93NEctQkE4Q1QzQTV4RFBrU0RhVXFmeUZnV3ZUT3l3Nmc3MzFraVRDT2Fvdkp3M3cxXy0yUmFhd3NnWm5uZ2pSZ3BqampMcGh0czl2ZWNFemJJYkZTcXdpd01PcS10NW1GSTBiYm5wMWhxc2xLTUlTSGkwT09lQVB4aFJvT0JfdVgzdXRnWnd6bnR3?oc=5","date":"2013-05-13","type":"regulatory","source":"Asian Scientist Magazine","summary":"Sagent Pharma To Acquire Remaining Interest In Chengdu Kanghong Pharma - Asian Scientist Magazine","headline":"Sagent Pharma To Acquire Remaining Interest In Chengdu Kanghong Pharma","sentiment":"neutral"}],"patents":[{"drugName":"Lidocaine Hydrochloride","drugSlug":"lidocaine-hydrochloride","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":10800000},{"drugName":"Dexamethasone","drugSlug":"dexamethasone","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":15600000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Teva Pharmaceutical Industries","Mylan N.V.","Endo International plc"],"therapeuticFocus":["Ophthalmology","Injectables"],"financials":{"source":"sec_edgar+yahoo","revenue":318296000,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":318296000,"period":"2015-12-31"},{"value":75199000,"period":"2015-09-30"},{"value":77345000,"period":"2015-06-30"},{"value":82645000,"period":"2015-03-31"},{"value":288983000,"period":"2014-12-31"},{"value":65359000,"period":"2014-09-30"}],"grossProfit":87739000,"grossProfitHistory":[],"rdSpend":29145000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-21882000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":28962000,"cashHistory":[],"totalAssets":349732000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}